mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
date-range is the range of dates corresponding to the given confidence level confidence indicates the confidence level for the given date range. For example, "cal 1220–1281 AD (1σ)" means a calibrated date for which the true date lies between AD 1220 and AD 1281, with a confidence level of '1 sigma', or approximately 68%. Calibrated dates can also be expressed as "BP" instead of using "BC" and "AD". The curve used to calibrate the results should be the latest available IntCal curve. Calibrated dates should also identify any programs, such as OxCal, used to perform the calibration. In addition, an article in Radiocarbon in 2014 about radiocarbon date reporting conventions recommends that information should be provided about sample treatment, including the sample material, pretreatment methods, and quality control measurements; that the citation to the software used for calibration should specify the version number and any options or models used; and that the calibrated date should be given with the associated probabilities for each range.
== Biosimilars == In December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kixelle, intended for the treatment of diabetes. The applicant for this medicinal product is Mylan IRE Healthcare Limited. Kixelle was approved for medical use in the European Union in February 2021. Kixelle was renamed to Kirsty. Trurapi was approved for medical use in Canada in October 2020. Truvelog and Truvelog Solostar were approved for medical use in Australia in October 2020. In October 2021, Kirsty was approved for medical use in Canada. In February 2022, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Truvelog Mix 30, intended for the treatment of diabetes. The applicant for this medicinal product is sanofi-aventis groupe. It was approved for medical use in the European Union in April 2022. In January 2024, the European Commission withdrew the marketing authorization for Truvelog Mix 30 (insulin aspart) in the European Union. The withdrawal was at the request of the marketing authorization holder, Sanofi Winthrop Industrie, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. In February 2025, insulin aspart-szjj, sold under the brand names Merilog and Merilog Solostar, is a biosimilar to Novolog that was approved for medical use in the United States in February 2025.
The commission noted that "the Russian intervention in Georgia was not limited to a “Blitz”-type action and was not solely focused on rescuing and evacuating Russian citizens." The commission said that "the constitutional obligation to protect Russian nationals [...] cannot serve as a justification for intervention under international law", adding that "Russian domestic law can [...] not be invoked as a justification for a breach of an international law." The commission suggested that "it seems abusive to rely on their need for protection as a reason for intervention, because Russia itself has created this reason for intervention". The commission concluded that "the Russian intervention in Georgia cannot be justified as a rescue operation for Russian nationals in Georgia."
== Criticisms == In 2013, studies of autologous bone marrow stem cells on ventricular function were found to contain "hundreds" of discrepancies. Critics report that of 48 reports, just five underlying trials seemed to be used, and that in many cases whether they were randomized or merely observational accepter-versus-rejecter, was contradictory between reports of the same trial. One pair of reports of identical baseline characteristics and final results, was presented in two publications as, respectively, a 578-patient randomized trial and as a 391-subject observational study. Other reports required (impossible) negative standard deviations in subsets of people or contained fractional subjects, negative NYHA classes. Overall, many more people were reported as having receiving stem cells in trials, than the number of stem cells processed in the hospital's laboratory during that time. A university investigation, closed in 2012 without reporting, was reopened in July 2013. In 2014, a meta-analysis on stem cell therapy using bone-marrow stem cells for heart disease revealed discrepancies in published clinical trial reports, whereby studies with a higher number of discrepancies showed an increase in effect sizes. Another meta-analysis based on the intra-subject data of 12 randomized trials was unable to find any significant benefits of stem cell therapy on primary endpoints, such as major adverse events or increase in heart function measures, concluding there was no benefit.
=== Periodicals === International Journal of Food Microbiology Foodborne Pathogens and Disease, ISSN 1535-3141, Mary Ann Liebert, Inc. Mycopathologia, ISSN 1573-0832 (electronic), ISSN 0301-486X (paper), Springer
Sources: en.wikipedia.org
=== Healthcare === Cyclo Olefin Polymer (COP) is gaining adoption in medical, pharmaceutical and life science applications by replacing or being used in combination with other materials, yielding superior products. There is no risk of pH shift from released alkali ions as there is in glass containers making it suitable for long-term storage of sensitive pharmaceuticals such as protein- or peptide-based drugs. COP has excellent dimensional stability and can reproducibly replicate micron-sized features of microfluidic devices and diagnostics with high aspect ratios. In applications involving vacuum COP is amenable to coating with silica via plasma-enhanced chemical vapor deposition (PECVD). These coated materials are used for blood collection tubes (vacutainers) to reduce mass and improve safety for clinical workers. Similarly, coated COP vials are used for lyophilized (freeze-dried) proteins to give a more predictable and consistent heat flow rate during the lyophilization process. In applications requiring liquid nitrogen temperatures COP vials are used over glass or other plastics because of their durability over a range of temperatures and for extended periods of time, without impacting the viability of the stored material. This makes COP a suitable material for storing both biopharmaceutical drug products as well as stem cells for cell therapies.
These decisions were unpopular with white South Africans, and as a concession the green-and-gold colours were adopted. NOCSA in 2004 merged with other bodies to form the South African Sports Confederation and Olympic Committee (SASCOC).
==== Youth development ==== Positive youth development focuses on the promotion of healthy development rather than viewing youth as prone to problems needing to be addressed. This is accomplished through programs and efforts by communities, schools, and government agencies.
L-RNA aptamers, built using L-ribose, are the enantiomers of natural oligonucleotides, which are made with D-ribose. Nucleic acid aptamers, including L-RNA aptamers, contain adenosine monophosphate, guanosine monophosphate, cytidine monophosphate, uridine monophosphate, a phosphate group, a nucleobase and a ribose sugar.
=== Fan works === The use of sandbox applications like Garry's Mod have allowed for Combine non-player characters to be used in a variety of webcomics and machinima productions. In one webcomic, Concerned, the Combine are portrayed as a highly bureaucratic and often inept organization. One issue shows a Civil Protection briefing for attempting to capture the comic's protagonist Gordon Frohman, in which officers are instructed to cluster around explosive barrels, seek cover on unstable structures and rappel down from bridges in front of fast moving vehicles. In another example, the machinima series Combine Nation follows Civil Protection officers in a similar style to police procedural documentaries. Other media portray the Combine with more serious overtones, such as the live-action video The Combine Interview, which parodies an interview with Tom Cruise discussing Scientology. The video, described by both Joystiq and Kotaku as "creepy", instead presents an interview with a Civil Protection officer discussing the Combine's rule of Earth, adapting Cruise's words to fit the Combine theme. PC Gamer UK noted that "the suggestion, of course, is that Scientology's purpose or self-image in some way resembles that of the homogenizing intergalactic murderous alien collective".
Sources: en.wikipedia.org
where δ2HA is the delta value of pool A relative to VSMOW. As many delta values do not vary greatly from one another the α value is often very close to unity. A related measure called epsilon (ε) is often used which is given simply by:
The cephalic phase: Thirty percent of the total gastric acid secretions to be produced is stimulated by anticipation of eating and the smell or taste of food. This signalling occurs from higher centres in the brain through the vagus nerve (Cranial Nerve X). It activates parietal cells to release acid and ECL cells to release histamine. The vagus nerve (CN X) also releases gastrin releasing peptide onto G cells. Finally, it also inhibits somatostatin release from D cells. The gastric phase: About sixty percent of the total acid for a meal is secreted in this phase. Acid secretion is stimulated by distension of the stomach and by amino acids present in the food. The intestinal phase: The remaining 10% of acid is secreted when chyme enters the small intestine, and is stimulated by small intestine distension and by amino acids. The duodenal cells release entero-oxyntin which acts on parietal cells without affecting gastrin.
Anglo Boer War - Home The Boer War, A 2 part documentary series shown on British television (1999). Scrapbook of Boer War, MSS P 456 at L. Tom Perry Special Collections, Harold B. Lee Library, Brigham Young University The Concentration Camps 1899–1902 by Hennie Barnard Archived 23 March 2020 at the Wayback Machine British Commanders of the Boer War, Link
== Applications == The primary use of this element is in automobiles as a catalytic converter, changing harmful unburned hydrocarbons, carbon monoxide, and nitrogen oxide exhaust emissions into less noxious gases. Of 30,000 kg of rhodium consumed worldwide in 2012, 81% (24,300 kg) went into this application, and 8,060 kg was recovered from old converters. About 964 kg of rhodium was used in the glass industry, mostly for production of fiberglass and flat-panel glass, and 2,520 kg was used in the chemical industry. In 2008, net demand (with the recycling accounted for) of rhodium for automotive converters made up 84% of the world usage, with the number fluctuating around 80% in 2015−2021.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.